Immunoglobulin-enriched milk fraction
A method using microfiltration and anion exchange chromatography enriches the IgA and IgM content in a milk fraction, addressing the low immunoglobulin levels in infant formulas and stabilizing Ig in the whey fraction, resulting in a high immunoglobulin-enriched product for nutritional compositions.
Patent Information
- Application Number
- JP2024534576
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-15
- Filing Date
- 2022-12-14
- Publication Date
- 2024-11-28
AI Technical Summary
Existing infant formulas lack a high proportion of immunoglobulin content, particularly IgA, which is crucial for mimicking the immunological protection provided by human breast milk, and the whey fraction from cheese production is often discarded despite containing significant Ig.
A method involving microfiltration, casein precipitation, and anion exchange chromatography to stabilize and enrich the immunoglobulins in a milk fraction, achieving a high IgA and IgM content compared to IgG, with a ratio of 60% by weight.
The process results in a milk fraction with 10-40% total immunoglobulin content and a (IgA+IgM)/IgG ratio of 25-60% by weight, suitable for enhancing the immunological properties of infant formulas.
Smart Images

Figure 2024544249000001 
Figure 2024544249000002 
Figure 2024544249000003
Abstract
Description
[Technical field]
[0001] The present invention relates to milk fractions with high immunoglobulin content, their production and uses. [Background technology]
[0002] Milk is the sole source of nutrition for mammalian offspring until they are able to digest food from other sources. Colostrum and milk of all lactating animals contain immunoglobulins (Ig) that provide the offspring with immunological defense against microbial pathogens and toxins and protect the mammary gland from infection. The major classes of immunoglobulins in bovine and human milk are IgG, IgA, and IgM, which differ in structure and biological activity. IgG can be subdivided into IgG1 and IgG2; IgA can be subdivided into IgA1 and IgAIgA2.
[0003] Immunoglobulins differ in molecular weight: monomeric IgG weighs about 150 kDa (the exact weight depends on the animal of origin), dimeric IgA about 400 kDa, and IgM about 900 kDa, considerably higher than the weight of the major whey proteins (about 14-18 kDa) and considerably smaller than the weight of the casein micelles present in milk.
[0004] The major Ig in human milk is IgA. Human breast milk contains about 85-90% by weight of IgA, about 2-3% by weight of IgG, and about 8-10% by weight of IgM, based on the total Ig content (JA Cakebread et al., J. Agric. Food Chem., 63 (2015) 7311-7316). The total Ig concentration in human breast milk is about 1.5 times the Ig content of bovine milk (JA van Neerven et al., J. Allergy Clin. Immunol., October 2012, 853-858). The predominant Ig in bovine milk is IgG. Mature bovine milk contains about 80% by weight IgG (of which the vast majority is IgG1), about 10% by weight IgM, and about 10% by weight IgA, based on the total Ig content.
[0005] The Ig content of bovine colostrum is much higher than that of mature bovine milk: Ig represents 70-80% of the total protein content of colostrum, whereas in mature bovine milk it provides only 1-2% by weight of the total protein content. The IgG / IgA ratio in colostrum is much higher than that in mature bovine milk.
[0006] Infant formulas are traditionally prepared by combining at least one whey protein source, at least one milk (casein) protein source, at least one lipid source, at least one carbohydrate source, vitamins, and minerals, with cow's milk being one of the sources used for these proteins, carbohydrates, lipids, and vitamins.
[0007] There is a continuing desire to produce infant formulas that are as close as possible to human breast milk. Therefore, in order to achieve this goal, it is desirable to increase the active immunoglobulin and IgA content of infant formulas. Thus, one of the objects of the present invention is the provision of a milk fraction that has a high ratio of IgA compared to IgG; thus, the addition of said milk fraction to infant formulas would meet this desire.
[0008] An efficient method for obtaining whey protein involves microfiltration of skim milk into a casein-rich retentate and a whey protein-rich filtrate.
[0009] The whey protein rich filtrate (i.e., serum protein fraction) resulting from microfiltration can be used to produce serum protein concentrate (SPC) by subjecting the filtrate to ultrafiltration to remove lactose, ash, and water, followed by (spray) drying.
[0010] From the casein-rich residue, a micellar casein isolate (MCI) can be obtained by subjecting the residue to evaporation and (spray) drying. For example, this MCI can be used in the production of soft cheeses such as Mozzarella and Feta. The whey fraction of this cheese manufacturing process is usually considered a waste product, despite the fact that it contains significant amounts of Ig. Therefore, another object of the present invention is to stabilize Ig within this whey fraction.
[0011] During microfiltration, most of the IgG settles out in the serum protein fraction, whereas the casein fraction contains most of the IgA and IgM, in addition to a not inconsiderable portion of IgG. Summary of the Invention [Means for solving the problem]
[0012] The present invention relates to a method for stabilizing immunoglobulins remaining in casein-rich MF retentate.
[0013] More specifically, the present invention relates to a milk fraction comprising an immunoglobulin content, defined as the total content of IgG+IgA+IgM, in the range of 10-40% by weight relative to the total protein content, and a weight ratio (IgA+IgM) / IgG in the range of 25-60% by weight, preferably 45-60% by weight.
[0014] The present invention also relates to a process for obtaining an Ig-enriched milk fraction, preferably enriched in IgA and IgM, comprising the steps of: a) subjecting skim milk to microfiltration to produce a micellar casein-rich MF filtrate and a whey protein-rich MF retentate; b) subjecting the MF retentate to a casein precipitation and / or cheese making process to produce a casein-rich fraction and a whey fraction; c) subjecting the whey fraction obtained in step b) to microfiltration and / or anion exchange chromatography to obtain an immunoglobulin-enriched milk fraction; The present invention relates to a process comprising: DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The first step in the process of the invention involves microfiltration of skimmed milk. The term "skimmed milk" refers to animal milk, preferably bovine milk, that has been skimmed and optionally pretreated (e.g., pasteurized, diluted, ultrafiltered, concentrated, desalted, and / or reduced in carbohydrate level), provided that the original percentage of casein to whey protein remains substantially unchanged.
[0016] Skim milk is subjected to microfiltration to obtain a casein-rich retentate and a whey protein-rich permeate, which is a well-known process. A variety of microfiltration membranes can be used, including spiral wound, ceramic, and hollow fiber membranes. The microfiltration membrane should be permeable to water, minerals, and lactose, at least partially permeable to whey proteins, and have high retention of casein proteins and fat. Suitable microfiltration membranes typically have pore sizes of 0.85-0.5 μm, more typically 0.1-0.2 μm. The microfiltration step is preferably carried out at a temperature in the range of 4 to 15°C or 50 to 55°C, more preferably in the range of 10 to 15°C or 50 to 52°C.
[0017] The cross flow is preferably high: preferably in the range of 0.10-0.25 m / sec for spiral wound membranes, 1.0-2.4 m / sec for hollow fiber membranes, and 5.0-7.0 m / sec for ceramic membranes.
[0018] If desired, the pH of the milk can be adjusted prior to microfiltration to adjust the ionic charge on the molecules and membranes. The pH is preferably in the range of 5.6 to 6.2, more preferably 5.6 to 6.0, most preferably 5.6 to 5.8.
[0019] The transmembrane pressure (TMP) is preferably as low as possible, more preferably in the range of 0.25 to 1 bar.
[0020] To further improve the separation between immunoglobulins, diafiltration is desirable.
[0021] The MF retentate is subjected to a casein precipitation and / or cheese making process to reduce the casein content of the MF retentate.
[0022] The casein precipitation process involves the addition of an acid to induce coagulation of casein, resulting in an acid casein fraction (casein curd) and an acid whey fraction. The acid is preferably selected from HCl, H2SO4, and citric acid.
[0023] For example, 1M H2SO4 can be added to skim milk with good stirring at 40-45°C until the pH reaches a range of 4.3-4.6. The acidified milk is stirred until curd formation is complete. The curds are then removed from the whey, for example by bag filtration or centrifugation.
[0024] The cheese making process preferably includes (i) the addition of a fat source to the MF residue, optionally after drying and resuspension of the MF residue, (ii) the subsequent addition of a coagulating agent and a soil acidifying agent, and (iii) coagulation to obtain a casein-rich fraction (cheese or cheese precursor) and a whey fraction. Suitable fat sources are anhydrous milkfat, anhydrous milkfat fractions, butter, butter oil, cream having a fat content in the range of 30-80% by weight, and mixtures of two or more of these, with anhydrous milkfat and cream being the preferred fat sources. The fat source is preferably added to the MF residue (or resuspended dry residue) at a temperature above the melting point of the fat source.
[0025] The target pH for acidification is preferably in the range of 4.8 to 5.7, more preferably 4.9 to 5.5. Suitable acidifying agents include starter cultures (bacterial acidifying agents that convert lactose to lactic acid), acids, acidulants (such as glucono-delta-lactone or GDL), and combinations of two or more thereof. The most common starter cultures include thermophilic starters, typically CSK, Chr. Hansen, or DuPont starters. Thermophilic starters by Chr. Hansen include frozen cultures STI-02, STI-03, STI-04, STI-06, and freeze-dried cultures STI-12, STI-13, and STI-14. Mesophilic starters may also be used.
[0026] Suitable coagulants are known in the art and include, for example, calf rennet, fermentation-produced rennet, and microbial rennet. Examples of calf rennet include Kalase, manufactured by CSK, and Naturen, manufactured by Chr. Hansen. Examples of fermentation-produced rennet include Fromase, manufactured by DSM, and Milase, manufactured by CSK. Examples of microbial rennet include Chy-Max, manufactured by Chr. Hansen, and Maxiren, manufactured by DSM. Other coagulants include pepsin and various proteolytic enzymes of plant origin.
[0027] The whey fraction remaining after the casein precipitation or cheese making process, i.e., the acid whey fraction or cheese whey fraction, respectively, is then subjected to microfiltration and / or anion exchange chromatography steps to produce an immunoglobulin-enriched milk fraction.
[0028] This microfiltration step is carried out with membranes having pore sizes in the range of 50-100 nm, or molecular weight cut-off (MWCO) in the range of 500-800 kDa. The pore size is determined by gas-liquid porometry, also known as capillary flow porometry (CFP), with perfluoroether as the wetting liquid.
[0029] MWCO is an experimentally determined parameter that represents the molecular weight of a particular solute molecule (in this case: dextran (2000 ppm aqueous solution)) that is rejected by the membrane at a level of 90%. The transmembrane pressure in this determination is approximately 30 psi, and dextran rejection is measured by determination of total organic carbon (TOC).
[0030] A membrane of the pore size or MWCO defined above is permeable to at least a portion of IgG, but less permeable to IgA and IgM, and therefore the resulting retentate, i.e. the milk fraction according to the invention, is enriched in IgA and IgM compared to IgG.
[0031] Microfiltration is preferably carried out after acidification of the whey fraction to a pH in the range 4-5. The crossflow used for microfiltration is preferably 0.10-0.25 m / s for spiral membranes or 5-7 m / s for ceramic membranes. The temperature used is preferably 10-15° C. The whey fraction is preferably concentrated by said microfiltration to a volumetric concentration factor (VCF) of at least 10 and is preferably followed by at least one step of diafiltration with an equal volume of ion-exchanged water. The retentate from the microfiltration step is enriched in Ig, especially IgA and IgM.
[0032] Anion exchange chromatography can be carried out with various types of resins, including weak and strong ion exchange resins, and with a variety of counterions. The terms "weak" and "strong" ion exchange are commonly known in the art. Strong ion exchangers can use a wide pH range (usually very acidic pH to very alkaline pH) because they do not significantly release the charge on their matrix once the ion exchanger is equilibrated. Strong anion exchange resins are typically characterized by the presence of quaternary ammonium groups.
[0033] Weak ion exchangers have a more specific range of pH values (usually acidic to about neutral pH for weak anion exchange materials) at which they will maintain their charge. Weak anion exchange groups are usually characterized by the absence of quaternary ammonium groups. A common weak anion exchange group is a tertiary amine group.
[0034] In a preferred embodiment, a strong anion exchange resin is used, more preferably an anion exchange resin having quaternary ammonium groups (e.g., Q Sepharose Big Beads). More preferably, the anion exchange resin is Cl - It is in the form of:
[0035] Anion exchange chromatography is preferably carried out by first adjusting the pH of the whey fraction to 6.5-7.0. By passing through the column, the whey fraction is enriched in Igs, especially IgA and IgM; impurity proteins, such as beta-lactoglobulin, bind to the resin and can be eluded from the column by rinsing with a low pH or high conductivity buffer (e.g. 1M NaCl).
[0036] It is also possible to combine microfiltration and anion exchange chromatography by first performing microfiltration and adjusting the pH of the retentate to 6.5-7.0 before loading said retentate onto an anion exchange column for further enrichment of Ig. Such a combination allows further enrichment of Ig up to about 6-8 fold compared to Ig in the whey fraction after cheese manufacture or casein precipitation.
[0037] The resulting product, referred to herein as "milk fraction", has a total immunoglobulin content, relative to the total protein content, in the range of 10-40% by weight and a weight ratio (IgA+IgM) / IgG in the range of 25-60% by weight, preferably 45-60% by weight. Total immunoglobulin content is defined as the total IgG+IgA+IgM content as determined by bovine IgG ELISA quantification set up as described by RL Valk-Weebera, T. Eshuis-de Ruiter, L. Dijkhuizen, and SS van Leeuwen, International Dairy Journal, Volume 110, November 2020, 104814. Total protein content is measured by using the well-known Kjeldahl nitrogen analysis method and a Kjeldahl coefficient of 6.38.
[0038] The immunoglobulin-enriched milk fraction according to the invention is particularly suitable for use as an ingredient in the manufacture of a nutritional composition, in particular a formula, which is selected from the group of infant formulas, follow-up formulas and growing-up formulas. The invention therefore further relates to a nutritional composition, typically a nutritional composition for children, such as a formula, in particular an infant formula, a follow-up formula or a growing-up formula.
[0039] Nutritional compositions, particularly milk formulas, can be prepared by combining the immunoglobulin-enriched milk fraction with at least a lipid source, a carbohydrate source, vitamins, and minerals.
[0040] The lipid source can be any lipid or fat suitable for use in formulas. Preferred fat sources include milk fat, safflower oil, egg yolk lipids, canola oil, olive oil, coconut oil, palm kernel oil, soybean oil, fish oil, palm oleic, high oleic sunflower oil, and high oleic safflower oil, as well as microbial fermentation oils containing long chain polyunsaturated fatty acids. In one embodiment, anhydrous milk fat is used. The lipid source can also be in the form of fractions derived from these oils, such as palm olein, medium chain triglycerides, and esters of fatty acids (e.g., arachidonic acid, linoleic acid, palmitic acid, stearic acid, docosahexaenoic acid, linoleic acid, oleic acid, lauric acid, capric acid, caprylic acid, caproic acid, etc.). A small amount of oil rich in preformed arachidonic and docosahexaenoic acids may be added, e.g., fish oil or microbial oil. The fat source preferably has a ratio of n-6 to n-3 fatty acids of about 5:1 to about 15:1, e.g., about 8:1 to about 10:1. In certain embodiments, the formula comprises an oil mixture comprising palmitic acid esterified to triacylglycerols, e.g., palmitic acid esterified at the sn-2 position of triacylglycerols is in an amount of 20% to 60% by weight of the total palmitic acid, and palmitic acid esterified at the sn-1 / sn-3 positions of triacylglycerols is in an amount of 40% to 80% by weight of the total palmitic acid.
[0041] Examples of vitamins and minerals that are preferably present in the formula include Vitamin A, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Vitamin E, Vitamin K, Vitamin C, Vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorus, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in the form of their salts.
[0042] Examples of carbohydrates preferably present in the formula are lactose, non-digestible oligosaccharides such as galactooligosaccharides (GOS) and / or fructooligosaccharides (FOS) and human milk oligosaccharides (HMO).
[0043] If necessary, the nutritional composition may contain emulsifiers and stabilizers, such as soy lecithin, citrate esters of mono- and diglycerides, etc. It may also contain other substances that may have beneficial effects, such as lactoferrin, nucleotides, nucleosides, etc. EXAMPLES
[0044] Example 1 A skim milk stream containing 270 ppm IgG, 30 ppm IgA, and 24 ppm IgM and with a total protein concentration of 3.9% by weight (Ig content relative to total protein: 0.84% by weight) was subjected to microfiltration using a spiral membrane with a pore size of 0.1 μm. The microfiltration was carried out at 15° C. After concentration and diafiltration, the MF retentate (MCI) was collected.
[0045] The resulting MF retentate (MCI) contained approximately 500 ppm IgG, 170 ppm IgA, and 100 ppm IgM, with a total protein concentration of 14.7%. The Ig content in the MF retentate was 0.52% (i.e., lower than that of skim milk) due to the permeation of IgG through the membrane compared to the total protein. On the other hand, the (IgA+IgM) / IgG ratio increased from approximately 22% by weight in skim milk to approximately 58% by weight in the MF retentate.
[0046] The MF retentate was then acidified to pH=4.3 with 2M H2SO4 at 42°C. The solution was allowed to stand for approximately 30 minutes to allow curd formation. The curd was then removed from the whey using a 100 μm bag filter. The resulting whey fraction still had the same Ig content, but the total protein content was reduced to 1.3 wt%, resulting in a total Ig content of 6 wt% based on total protein.
[0047] The whey fraction, pH 4.3, was passed through a spiral MF membrane with a pore size of 500 kD (membrane area 6.7 m 2 ). Microfiltration was carried out at 15°C. A TMP of 0.5 bar was used and the cross flow was 80 l / min. The whey was concentrated to a VCF of 12 and the retentate was diafiltered once against an equal volume of demineralized water. The retentate had a total Ig content of 13% by weight based on total protein. The (IgA+IgM) / IgG ratio remained at 58% by weight.
[0048] Example 2 The pH of the whey fraction was adjusted to 7, and the whey fraction was then subjected to anion exchange chromatography (to remove quaternary ammonium functional groups and Cl) at a flow rate of 30 BV / hour (bed volume per hour) at room temperature. - Example 1 was repeated, except that the whey fraction was subjected to a 20% column purification procedure (using a strong anion exchange resin with counter ions). Three bed volumes of the whey fraction were fed to the column and collected at the outlet of the column. The collected product had a total Ig content of 20% by weight based on total protein, with an unchanged (IgA+IgM) / IgG ratio (58% by weight).
[0049] The column was then spun with 1M NaCl solution at a flow rate of 10 BV / hr to remove bound impurities; mainly beta-lactoglobulin.
[0050] Example 3 Example 1 was repeated, except that the MF retentate obtained at the end of Example 1 was neutralized to pH 7 and subjected to anion exchange according to the procedure of Example 2. The resulting product had a total Ig content of 25% by weight, based on total protein. No change in the (IgA+IgM) / IgG ratio (58% by weight) was observed.
Claims
1. 1. A method for obtaining a milk fraction enriched in immunoglobulins, preferably enriched in IgA and IgM, comprising: a) subjecting skim milk to microfiltration to produce a micellar casein-rich MF filtrate and a whey protein-rich MF retentate; b) subjecting the MF retentate to a casein precipitation or cheese making process to produce a casein-rich fraction and a whey fraction; c) subjecting the whey fraction obtained in step b) to microfiltration and / or anion exchange chromatography to obtain an immunoglobulin-enriched milk fraction. The method includes:
2. 2. The method of claim 1, wherein prior to microfiltration the pH of the skim milk is adjusted to a value in the range of 5.6 to 6.2, more preferably 5.6 to 6.0, most preferably 5.6 to 5.
8.
3. 3. The method of claim 1 or 2, wherein the cheese making process comprises (i) adding a fat source to the MF residue, optionally after drying and resuspension of the MF residue, (ii) subsequent addition of a coagulating agent and a soil acidifying agent, and (iii) coagulation to obtain a casein-rich fraction and a whey fraction.
4. 4. The method according to any one of claims 1 to 3, wherein the whey fraction obtained in step b) is acidified to a pH in the range of 4 to 5 before being subjected to microfiltration in step c).
5. 5. The method according to any one of claims 1 to 4, wherein the microfiltration of step c) is carried out with a membrane having a pore size in the range of 50-100 nm or a molecular weight cut-off (MWCO) in the range of 500-800 kDa.
6. 6. The method according to any one of claims 1 to 5, wherein the microfiltration of step c) is carried out by a spiral membrane with a cross-flow of 0.10 to 0.25 m / s or by a ceramic membrane with a cross-flow of 5 to 7 m / s.
7. 7. The method according to any one of claims 1 to 6, wherein the microfiltration of step c) is carried out at a temperature in the range of 10 to 15°C.
8. 8. The method according to any one of claims 1 to 7, wherein the whey fraction obtained in step b) is acidified to a pH in the range of 6.5 to 7 before being subjected to anion exchange chromatography.
9. A milk fraction comprising a content of immunoglobulins in the range of 10-40% by weight, relative to the total protein content, and a weight ratio (IgA+IgM) / IgG in the range of 25-60% by weight, preferably 45-60% by weight.
10. A nutritional composition selected from infant formula, follow-on formula, and growing-up milk, comprising the milk fraction of claim 9.
11. 11. A method of producing the nutritional composition of claim 10 by combining the milk fraction of claim 9 with at least a fat source, a carbohydrate source, a whey protein source, and vitamins and minerals.
Citation Information
Patent Citations
Sequential separation of whey protein and its formulation
JP2001516599A
Acid-soluble protein of micellar casein
JP2007525404A
Fresh cheese and method for producing the same
JP2008017814A
Immunoglobulin fractionation and the process for doing so
JP2008540462A
Method for producing a milk protein composition
JP2014514929A
